AU2012242784B2 - Peptide mimetic ligands of polo-like kinase 1 polo box domain and methods of use - Google Patents

Peptide mimetic ligands of polo-like kinase 1 polo box domain and methods of use Download PDF

Info

Publication number
AU2012242784B2
AU2012242784B2 AU2012242784A AU2012242784A AU2012242784B2 AU 2012242784 B2 AU2012242784 B2 AU 2012242784B2 AU 2012242784 A AU2012242784 A AU 2012242784A AU 2012242784 A AU2012242784 A AU 2012242784A AU 2012242784 B2 AU2012242784 B2 AU 2012242784B2
Authority
AU
Australia
Prior art keywords
alkyl
compound
aryl
optionally substituted
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2012242784A
Other languages
English (en)
Other versions
AU2012242784A1 (en
Inventor
Terrence R. Burke
Kyung S. Lee
Fa Liu
Jung-Eun Park
Wenjian QIAN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
United States Department of Health and Human Services
Original Assignee
Government of the United States of America
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Government of the United States of America filed Critical Government of the United States of America
Publication of AU2012242784A1 publication Critical patent/AU2012242784A1/en
Application granted granted Critical
Publication of AU2012242784B2 publication Critical patent/AU2012242784B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/006—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length of peptides containing derivatised side chain amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0827—Tripeptides containing heteroatoms different from O, S, or N
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/11—Protein-serine/threonine kinases (2.7.11)
    • C12Y207/11021—Polo kinase (2.7.11.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
AU2012242784A 2011-04-12 2012-04-12 Peptide mimetic ligands of polo-like kinase 1 polo box domain and methods of use Ceased AU2012242784B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161474621P 2011-04-12 2011-04-12
US61/474,621 2011-04-12
US201261588470P 2012-01-19 2012-01-19
US61/588,470 2012-01-19
PCT/US2012/033259 WO2012142245A2 (en) 2011-04-12 2012-04-12 Peptide mimetic ligands of polo-like kinase 1 polo box domain and methods of use

Publications (2)

Publication Number Publication Date
AU2012242784A1 AU2012242784A1 (en) 2013-10-31
AU2012242784B2 true AU2012242784B2 (en) 2017-04-13

Family

ID=46147674

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2012242784A Ceased AU2012242784B2 (en) 2011-04-12 2012-04-12 Peptide mimetic ligands of polo-like kinase 1 polo box domain and methods of use

Country Status (6)

Country Link
US (1) US10266565B2 (enExample)
EP (1) EP2686342A2 (enExample)
JP (1) JP2014511877A (enExample)
AU (1) AU2012242784B2 (enExample)
CA (1) CA2832073A1 (enExample)
WO (1) WO2012142245A2 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014153101A2 (en) 2013-03-14 2014-09-25 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Peptide and peptide mimetic binding antagonists of polo-like kinase 1 polo box domain and methods of use
KR101672975B1 (ko) * 2014-07-03 2016-11-04 한국과학기술연구원 알로스테릭 ｐｌｋ1-ｐｂｄ 저해활성을 가지는 고리형 포스포펩티드 화합물
KR101650778B1 (ko) * 2014-10-17 2016-08-25 충북대학교 산학협력단 폴로유사인산화효소-1의 폴로박스 도메인에 특이적으로 결합하는 펩타이드 유사체 및 이를 유효성분으로 포함하는 피임용 조성물
KR101670770B1 (ko) * 2014-10-17 2016-11-01 충북대학교 산학협력단 폴로유사인산화효소-1의 폴로박스 도메인에 특이적으로 결합하는 펩타이드 유사체 및 이를 포함하는 항암용 조성물
WO2017082924A1 (en) 2015-11-13 2017-05-18 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Peptide and peptide mimetic binding antagonists of polo-like kinase 1 polo box domain and methods of use
WO2018085208A1 (en) 2016-11-02 2018-05-11 The Research Foundation For The State University Of New York Methods of inhibiting viruses using compositions targeting tsg101-ubiquitin interaction
US20210322575A1 (en) 2018-09-28 2021-10-21 Nutcracker Therapeutics, Inc. Lipid nanoparticle formulations comprising lipidated cationic peptide compounds for nucleic acid delivery
CN115873033B (zh) * 2022-12-28 2025-03-18 永农生物科学有限公司 一种草铵膦的制备方法
WO2025206344A1 (ja) * 2024-03-28 2025-10-02 日産化学株式会社 グラフェンリンカー化合物及び電界効果トランジスタバイオセンサー

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010132869A2 (en) * 2009-05-15 2010-11-18 Government Of The U.S.A., As Represented By The Secretary, Department Of Health And Human Services Peptide mimetic ligands of polo-like kinase 1 polo box domain and methods of use

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100523215C (zh) 2000-12-01 2009-08-05 马普科技促进协会 介导rna干涉的小rna分子

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010132869A2 (en) * 2009-05-15 2010-11-18 Government Of The U.S.A., As Represented By The Secretary, Department Of Health And Human Services Peptide mimetic ligands of polo-like kinase 1 polo box domain and methods of use

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Bhadra D. et al. "Pegnology: A review of PEG-ylated systems" Die Pharmazie (2002) 57(1): 5-29 *
Khedkar A. et al. "A dose range finding study of novel oral insulin (IN-105) under fed conditions in type 2 diabetes mellitus subjects" Diabetes, Obesity and Metabolism (2010) 12(8): 659-664 *
Miller M.A. et al. "Amphiphilic Conjugates of Human Brain Natriuretic Peptide Designed for Oral Delivery: In Vitro Activity Screening" Bioconjugate Chem. (2006) 17: 267-274 *
Yun Sang-Moon et al. "Structural and functional analyses of minimal phosphopeptides targeting the polo-box domain of polo-like kinase 1" Nature Structural & Molecular Biology (2009) 16(8): 876-882 *

Also Published As

Publication number Publication date
US10266565B2 (en) 2019-04-23
WO2012142245A8 (en) 2013-11-21
EP2686342A2 (en) 2014-01-22
JP2014511877A (ja) 2014-05-19
WO2012142245A2 (en) 2012-10-18
US20140142044A1 (en) 2014-05-22
WO2012142245A3 (en) 2012-12-27
AU2012242784A1 (en) 2013-10-31
CA2832073A1 (en) 2012-10-18

Similar Documents

Publication Publication Date Title
US10266565B2 (en) Peptide mimetic ligands of polo-like kinase 1 polo box domain and methods of use
US7579318B2 (en) Cell penetrating peptides for intracellular delivery of molecules
CA2632451C (en) Cell penetrating peptides for intracellular delivery of molecules
US10047122B2 (en) Peptide and peptide mimetic binding antagonists of polo-like kinase 1 polo box domain and methods of use
AU2019207534B2 (en) Proteinaceous molecules and uses therefor
EP3256484B1 (en) Non-membrane disruptive p53 activating stapled peptides
US9175038B2 (en) Peptide mimetic ligands of polo-like kinase 1 polo box domain and methods of use
US20210379071A1 (en) Inhibitors of human immunodeficiency virus replication
EP4512426A1 (en) Compound and use thereof
EP3986438B1 (en) P53 activator peptidomimetic macrocycles
EP1795539B1 (en) Cell penetrating peptides for intracellular delivery of molecules
US10905769B2 (en) Peptide and peptide mimetic binding antagonists of polo-like kinase 1 polo box domain and methods of use
US20130345115A1 (en) Nuclear penetrating h4 tail peptides for the treatment of diseases mediated by impaired or loss of p53 function
US8916679B2 (en) Peptides binding to the dimer interface of thymidylate synthase for the treatment of cancer
AU2018302855A1 (en) Peptide derivative and pharmaceutical composition containing same
Class et al. Patent application title: PEPTIDE AND PEPTIDE MIMETIC BINDING ANTAGONISTS OF POLO-LIKE KINASE 1 POLO BOX DOMAIN AND METHODS OF USE Inventors: Wenjian Qian (Frederick, MD, US) Jung Eun Park (Bethesda, MD, US) Christopher C. Lai (Ellicott City, MD, US) James A. Kelley (Silver Spring, MD, US) Kyung S. Lee (Gaithersburg, MD, US) Terrence R. Burke, Jr.(Bethesda, MD, US)
US12441762B2 (en) Hepatitis c virus NS3/4A protease inhibitors
WO2013030541A1 (en) Histone deacetylase
WO2013081233A1 (ko) 암세포 특이적 세포괴사 유도 및 암 소멸 효과를 나타내는 세포사 유도 융합 펩타이드
CA3249979A1 (en) Compound and use thereof
Huo Design, synthesis, and evaluation of pentapeptides that inhibit the function of heat shock protein 70
WO2017082924A1 (en) Peptide and peptide mimetic binding antagonists of polo-like kinase 1 polo box domain and methods of use

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired